
==== Front
Arthritis Res Ther
Arthritis Res Ther
Arthritis Research & Therapy
1478-6354
1478-6362
BioMed Central London

3387
10.1186/s13075-024-03387-6
Research
Association of anti-HMGCR antibodies of the IgM isotype with refractory immune-mediated necrotizing myopathy
Yang Hongxia 12
Sun Chao 1
Ye Lifang 1
Xu Yuetong 1
Lin Sang 1
Peng Qinglin 1
Wang Guochun 1
Lu Xin luxin_n@163.com

1
1 https://ror.org/037cjxp13 grid.415954.8 0000 0004 1771 3349 Department of Rheumatology, Key Lab of Myositis, China-Japan Friendship Hospital, 2 Yinghua Road, Chaoyang District, Beijing, China
2 https://ror.org/02z1vqm45 grid.411472.5 0000 0004 1764 1621 Department of Clinical Laboratory, Peking University First Hospital, Beijing, China
11 9 2024
11 9 2024
2024
26 1581 7 2024
25 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Objective

Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) autoantibodies are one of the myositis-specific antibodies which is associated with immune-mediated necrotizing myopathy (IMNM). However, the relationship between anti-HMGCR isotypes and prognosis has not yet been fully investigated. This study was conducted to gain insight into the association between anti-HMGCR isotypes and clinical, and prognosis in IMNM patients who were positive for anti-HMGCR antibodies.

Methods

Levels of anti-HMGCR isotypes (IgG, IgA and IgM) were assessed by enzyme-linked immunosorbent assay (ELISA) in 123 consecutive serum samples obtained from 71 patients who were positive for anti-HMGCR IgG at baseline. Disease activity was assessed by manual muscle testing (MMT) 8, Physician’s Global Assessment (PGA) visual analog scale (VAS), and muscle VAS.

Results

Baseline anti-HMGCR IgG levels were correlated with PGA VAS (r = 0.24; p = 0.04), muscle VAS (r = 0.32; p < 0.01), and MMT8(r=-0.24; p = 0.04), and baseline anti-HMGCR IgM levels were positively correlated with PGA VAS (r = 0.27, p = 0.02), muscle VAS (r = 0.24, p = 0.04). Anti-HMGCR IgM positive patients had a lower age of onset [29(25,46) vs. 51(33,65), p = 0.006], and a higher proportion of neck weakness (63.5% vs. 34.6%, p = 0.031) compared with anti-HMGCR IgM negative patients. Longitudinal analysis showed that the changes in anti-HMGCR IgG levels were correlated with the changes in the PGA VAS (β = 3.830; p < 0.0001), muscle VAS (β = 2.893; p < 0.0001), MMT8 (β=-19.368; p < 0.0001), and creatine kinase (CK) levels (β = 3900.05, p < 0.0001). Anti-HMGCR IgM levels were weakly correlated with anti-HMGCR IgA levels at baseline (r = 0.33, p < 0.01), and the variations in anti-HMGCR IgA levels were correlated with the changes in anti-HMGCR IgM levels during follow-up (β = 0.885; p < 0.0001). There were more patients with anti-HMGCR IgM who showed a refractory course than those who were with anti-HMGCR IgM negative (polycyclic course: 40% vs. 25%; chronic continuous course: 46.7% vs. 20.5%, p = 0.018).

Conclusion

In anti-HMGCR IgG-positive IMNM patients, the levels of anti-HMGCR IgG are associated with disease activity, and anti-HMGCR IgM is associated with refractory outcome and poor prognosis.

Supplementary Information

The online version contains supplementary material available at 10.1186/s13075-024-03387-6.

Rheumatology key messages

• Anti-HMGCR IgM-positive patients had a younger age of onset and more neck weakness than anti-HMGCR IgM-negative patients.

• The levels of anti-HMGCR IgG and IgM are associated with disease activity in anti-HMGCR-positive patients.

• Anti-HMGCR IgM is associated with refractory outcome and poor prognosis.

Supplementary Information

The online version contains supplementary material available at 10.1186/s13075-024-03387-6.

Keywords

Immune-mediated necrotizing myopathy
Anti-HMGCR
Autoantibodies isotypes
Outcome
the National High Level Hospital Clinical Research Funding022-NHLHCRF-YS-02 022-NHLHCRF-YS-02 022-NHLHCRF-YS-02 022-NHLHCRF-YS-02 022-NHLHCRF-YS-02 022-NHLHCRF-YS-02 022-NHLHCRF-YS-02 022-NHLHCRF-YS-02 http://dx.doi.org/10.13039/501100004826 Natural Science Foundation of Beijing Municipality 7232145 7232145 7232145 7232145 7232145 7232145 7232145 7232145 issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) antibodies are considered to be one of the myositis-specific antibodies (MSA) in immune-mediated necrotizing myopathy (IMNM) [1]. IMNM patients with anti-HMGCR antibodies are characterized by refractory muscle weakness and significantly elevated creatine kinase (CK) levels [2]. In daily clinical practice, the clinical phenotype and prognosis of anti-HMGCR-positive IMNM are heterogeneous. Approximately 63% of anti-HMGCR-positive patients have a history of statin exposure, and patients without a history of statin exposure have more severe muscle weakness and poorer immunosuppressive response than those with a history of statin exposure [3, 4]. In addition, younger patients with anti-HMGCR antibodies have more severe muscle weakness and slower recovery than older patients [5–8].

Anti-HMGCR antibodies can also be classified as IgG, IgA, or IgM according to their immunoglobulin isotype. In clinical practice, anti-HMGCR positivity is usually based on the presence of IgG isotype of anti-HMGCR antibodies. In previous studies, anti-HMGCR titers were correlated with muscle strength and serum CK levels, and decreases in anti-HMGCR are associated with improvements in muscle strength and decreases in CK levels after treatment [3, 9–11]. Classical complement pathway activation and in vitro experiments show that anti-HMGCR autoantibodies are pathogenic [12–14].

However, the relationship between anti-HMGCR isotypes and disease outcome has not yet been fully investigated. Therefore, we aimed to investigate the association between the presence and levels of anti-HMGCR antibodies of the IgG, IgM, and IgA isotypes and disease outcome in anti-HMGCR IgG-positive IMNM.

Patients and methods

Patients

This study enrolled 71 anti-HMGCR IgG-positive IMNM patients hospitalized at the Department of Rheumatology and Immunology of China-Japan Friendship Hospital from 2014 to 2022. The diagnosis of IMNM was made according to criteria of the European Neuromuscular Center in 2017 [1]. Anti-HMGCR IgG was tested by enzyme-linked immunosorbent assay (ELISA) (Inova Diagnostics Inc., San Diego, CA, USA) according to the manufacturer’s protocol, and levels > 0.15U/ml were considered positive. Neuromuscular diseases with genetic confirmation were excluded.

In addition, 47 patients with idiopathic inflammatory myositis (IIM) who were positive for other MSA but negative for anti-HMGCR IgG and 33 age and sex-matched healthy controls (HCs) without IIM were included in this study. The diagnosis of IIM was based on the 2017 European League Against Rheumatism/American College of Rheumatology IIM criteria [15].

The demographic, clinical and laboratory characteristics of the enrolled patients were retrospectively collected from the inpatient medical record system. The diagnosis of interstitial lung diseases(ILD) was based on high-resolution chest computed tomography and abnormal pulmonary function tests [16]. Skin involvement included mechanic’s hand, Gottron’s sign, heliotrope sign, and Raynaud’s phenomenon. Muscle atrophy was diagnosed by muscle magnetic resonance imaging. Medical Research Council (MRC) scale (grades 0–5), and Manual Muscle Testing in 8 muscles (MMT-8) were used for the muscle measurements. Severe muscle weakness was defined as a grade ≤ 3 for muscle strength on the MRC scale in any muscle at presentation [17].

Disease activity was assessed using the core set of measures developed by the International Myositis Assessment and Clinical Studies Group (IMACS) [18–20]. All patients were assessed for disease activity using the MMT-8, the Physician’s Global Assessment (PGA) visual analog scale (VAS; range: 0–10 cm), and the muscle VAS.

Follow-up design

The follow-up time was defined as the interval between the diagnosis of myositis and the last follow-up. The survival status of all anti-HMGCR IgG-positive patients was obtained by telephone or medical record follow-up. All patients had at least one follow-up visit.

Patients were defined as in remission if they met the following criteria and remained in remission for at least 6 months CK < 500 U/L and MMT8 ≥ 75, and PGA VAS ≤ 1 cm. Relapse was defined as a decrease in MMT8 > 20% compared to baseline, worsening of PGA VAS ≥ 2 cm, and CK > 2000U/L or a doubling of CK levels increased compared to the previous visit [21]. Clinical courses were defined as monocyclic (complete recovery within 2 years without a relapse, with or without medical therapy), chronic polycyclic (prolonged, relapsing course with ≥ 1 relapse during ≥ 2 years of observation), chronic continuous (persistent disease activity for > 2 years, never remission during full-time follow-up despite medical therapy). Patients whose disease evolution was < 1 year were not assessed for clinical outcome [22].

The study was conducted in accordance with the tenets of the Declaration of Helsinki, and was approved by the Ethics Review Committee of the China-Japan Friendship Hospital (approval number: 2019-SDZL-3). Written informed consent was obtained from all patients.

Measurement of anti-HMGCR isotypes by ELISA

The levels of anti-HMGCR isotypes (IgG, IgA and IgM) were measured by ELISA in the sera of 71 anti-HMGCR-positive patients, 47 anti-HMGCR-negative IIM patients, and 33 HCs. The levels of anti-HMGCR isotypes in the follow-up sera obtained from anti-HMGCR Ig G-positive patients were also examined. All serum samples were stored at -80℃ for the detection of anti-HMGCR antibodies.

Anti-HMGCR-IgG levels were measured by ELISA (Inova Diagnostics, Inc., San Diego, CA, USA) according to the manufacturer’s protocol, using a cut-off value of 0.15 U/ml. Horseradish peroxidase (HRP)-conjugated goat anti-human IgA polyclonal antibody (1:5000; A18781; Thermo Fisher Scientific) and mouse anti-human IgM-HRP (1:4000; cat. no.9020-05; Southern Biotech) were used as secondary antibodies to test for the presence of anti-HMGCR antibody isotypes (IgA, IgM) in serum. Serum samples were diluted 1:200 for the anti-HMGCR IgA test and 1:400 for the anti-HMGCR IgM test, respectively. Antibody units were calculated from the resulting optimal densities at 450 nm (A450). The absorbance of each well was read at 450 nm and the anti-HMGCR antibody levels were calculated according to the manufacturer’s instructions: unit value (U/ml) = [A450(sample)-A450(negative control)/ [A450(positive control)-A450(negative control)]. All samples were examined in duplicate, and the mean of the two assays was used as the final value for statistical analysis.

Detection of MSA

All samples were screened for anti-TIF1-γ, anti-NXP2, anti-Mi2, anti-MDA5, anti-SAE, anti-Jo-1, anti-PL-7, anti-PL-12, anti-EJ, and anti-SRP autoantibodies by line immunoassay (EUROIMMUN, Lübeck, Germany) according to manufacturer’s protocol.

Statistical analysis

Categorical data are expressed as frequencies (%), whereas continuous variables are presented as mean ± standard deviation(SD) if normally distributed, or median and interquartile range (IQR) if not. Comparisons between groups were made using Fisher’s exact test, chi-square test, or Mann-Whitney test as appropriate. Spearman’s rank correlation analysis was used to examine the association between the levels of anti-HMGCR antibodies and clinical and pathological parameters. Generalized estimating equations (GEE) were used to analyze the longitudinal correlations between anti-HMGCR levels and disease activity. Time to remission was used as an indicator to evaluate the outcome. All variables were included in the univariate analysis, and predictors with p < 0.05 in univariable analysis were included in the multivariable Cox regression analysis. Statistical analyses were performed using SPSS version 26 (SPSS, Inc., Chicago, IL, USA) and GraphPad Prism 8.0 (GraphPad Software, San Diego, CA, USA). P values < 0.05 were considered statistically significant.

Results

Evaluation of the isotypes of anti-HMGCR antibodies

We determined cut-off values for anti-HMGCR IgA and Ig M using the mean value of the HCs plus two SD or 3SD. When the cut-off value was set to mean + 2SD (0.25U/ml for anti-HMGCR IgA and 0.41 U/ml for anti-HMGCR IgM), the positivity rates of Ig M and Ig A were 26.8% and 23.9%, respectively, and the specificity was 87.2% and 89.4%, respectively. When the cut-off value was set tomean + 3SD (0.32U/ml for anti-HMGCR IgA and 0.50 U/ml for anti-HMGCR IgM), the positivity rates of Ig M and Ig A were 15.5% and 28.3%, respectively, and the specificity was 100% and 93.6%, respectively. Indeed, there is a lower positivity rate and more significant specificity when the cut-off value is set to mean + 3SD (Supplementary Fig. 1 and Supplementary Table 1). Different cut-off values in our analyses did not affect the conclusions of our study. We use mean + 2SD as the cut-off value in subsequent analyses.

Correlation between baseline anti-HMGCR isotypes levels and disease activity

Analysis of the correlation between baseline anti-HMGCR isotype levels and disease activity showed that baseline anti-HMGCR IgG levels were significantly positively correlated with PGA VAS (r = 024, p = 0.04), muscle VAS (r = 0.32, p < 0.01), and negatively correlated with MMT8 (r=-0.24, p = 0.04) (Fig. 1A-C). Baseline anti-HMGCR IgM levels were positively correlated with PGA VAS (r = 0.27, p = 0.02), Muscle VAS (r = 0.24, p = 0.04) (Fig. 1G, H, I), while no correlation was found between anti-HMGCR IgA levels and disease activity (Fig. 1D, E, F).

Fig. 1 Correlation between baseline anti-HMGCR Ig G (A-C), IgA(D-F), and IgM(G-I) levels and disease activity.Abbreviation: HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; PGA, Physician’s Global Assessment; VAS, Visual Analog Scale; MMT, manual muscle testing

Characteristics of anti-HMGCR patients stratified by anti-HMGCR IgM phenotype

Seventy-one patients who were positive for anti-HMGCR IgG detected by ELISA were included in the study. The enrolled patients were 45 females (63.4%) and 26 males (36.6%), with an onset age of [46 (29,61; IQR)] years. The duration from onset to diagnosis was [12(5,24; IQR)] months, and 15 patients (21.1%) had a history of statin use.

Since anti-HMGCR Ig M levels were correlated with disease activity, we compared the characteristics of patients with anti-HMGCR IgM positive and anti-HMGCR IgM negative. Of the 71 anti-HMGCR IgG positive patients, 19 patients (26.7%) were also positive for anti-HMGCR IgM. Compared with anti-HMGCR IgM negative patients, anti-HMGCR IgM positive patients had a lower age of onset [29(25,46) vs. 51(33,65), p = 0.006], and a higher proportion of neck weakness (63.5% vs. 34.6%, p = 0.031). Meanwhile, anti-HMGCR IgM positive patients had higher levels of anti-HMGCR IgA [0.22(0.12,0.42) vs. 0.12(0.06,0.18), p = 0.006] than anti-HMGCR IgM negative patients (Table 1). Anti-HMGCR IgM levels at baseline were weakly correlated with anti-HMGCR IgA levels (r = 0.327, p = 0.005), but anti-HMGCR IgG levels at baseline were not correlated with either anti-HMGCR IgA or anti-HMGCR IgM levels (Supplementary Fig. 2).

Table 1 Baseline characteristics of all IMNM patients who were positive for anti-HMGCR IgG + patients

Characteristics	All patients(N = 71)	Anti-HMGCR IgM+(n = 19)	Anti-HMGCR IgM-(n = 52)	p value	
Female	45(63.4%)	13(68.4%)	32(61.5%)	0.594	
Age of onset, median (IQR), years	46(29, 61)	29(25,46)	51(33,65)	0.006	
Time from onset to diagnosis, median (IQR), months	12(5,24)	11.5(4.3,24)	12(6,28)	0.526	
Statin history	15(21.1%)	2(10.5%)	13(25%)	0.186	
Treatment naive	23(32.4%)	6(31.8%)	17(32.7%)	0.929	
Muscle weakness	64(90.1%)	18(94.7%)	46(88.5%)	0.666	
 Severe muscle weakness*	51(79.7%)	16(84.2%)	32(61.5%)	0.071	
 Dysphagia	15(21.1%)	5(26.3%)	10(19.2%)	0.517	
 Neck weakness	30(42.3%)	12(63.5%)	18(34.6%)	0.031	
 MMT8	60(51,72)	54(44,72)	63(52,72)	0.129	
Muscle atrophy	8(11.3%)	1(5.3%)	7(13.5%)	0.333	
Myalgia	19(26.8%)	6(31.6%)	13(25%)	0.579	
Fever	4(5.6%)	1(5.3%)	3(5.8%)	0.935	
Loss of weight	20(28.2%)	4(21.1%)	16(30.8%)	0.420	
Arthritis	8(11.3%)	2(10.5%)	6(11.5%)	0.905	
Skin involvement	12(16.9%)	6(31.6%)	6(11.5%)	0.071	
Interstitial lung diseases	13(18.3%)	2(10.5%)	11(21.2%)	0.305	
Malignant tumor	3(4.2%)	2(10.5%)	1(1.9%)	0.111	
Other connective tissue diseases	8(11.3%)	2(10.5%)	6(11.5%)	1	
ALT, median (IQR), IU/L	123(54,224)	155(57,227)	119(47,254)	0.599	
AST, median (IQR), IU/L	64(32,122)	86(29,122)	59(35,122)	0.823	
LDH, median (IQR), IU/L	542(299,792)	569(296,854)	526(303,778)	0.851	
CK, median (IQR), IU/L	2385(800,4790)	1812(552,4899)	2395(859,4423)	0.886	
Anti-HMGCR characteristics					
IgG level, median (IQR), U/ml	0.34(0.20,0.50)	0.38(0.22,0.55)	0.33(0.20,0.48)	0.879	
IgA positive(> 0.25U/ml)	17(23.5%)	8(42.1%)	9(17.3%)	0.056	
IgA level, median (IQR), U/ml	0.13(0.08,0.24)	0.22(0.12,0.42)	0.12(0.06,0.18)	0.006	
* severe muscle weakness was defined as a grade ≤ 3 for muscle strength in Medical Research Council scale

Abbreviations: HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; MMT, manual muscle testing; ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDH, lactic dehydrogenase; CK, creatine kinase

All 71 enrolled anti-HMGCR positive patients underwent muscle biopsy. When we compared the muscle pathological features of anti-HMGCR IgM positive and anti-HMGCR IgM negative patients, a higher proportion of anti-HMGCR IgM positive patients showed connective tissue hyperplasia on muscle pathology (57.9% vs. 30.8%, p = 0.037). There were no significant differences between the two groups of patients in other pathological manifestations (Supplementary Table 2). Methods for assessing muscle pathology are presented in the Supplementary Methods.

Changes of anti-HMGCR IgG, IgA, and IgM isotypes over time

Thirty-three patients had one or more follow-up visits, 10 patients experienced a shift to negative of anti-HMGCR Ig G during follow-up, and 3 patients were anti-HMGCR IgG negative at the last visit. In contrast, 8 patients (24.2%) experienced negative-positive conversion of the IgM isotype of anti-HMGCR antibodies, and 11 patients (33.3%) experienced a positive conversion of IgA antibodies (Fig. 2 and Supplementary Table 3).

Fig. 2 Changes of anti-HMGCR IgG (A), IgA (B), and IgM (C) during follow-up in 33 patients with one or more follow-up visits. Changes of anti-HMGCR IgG in 10 patients with IgG negative-positive conversion(D), changes of anti-HMGCR IgA in 11 patients with a positive conversion of IgA(E), and changes of anti-HMGCR IgM in 8 patients with negative-positive conversion of the IgM (F) over time. Abbreviations: HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase

Longitudinal relationship between anti-HMGCR autoantibody levels and disease activity

Thirty-three patients had one or more follow-up visits. We analyzed the correlation between anti-HMGCR isotype levels and disease activity 33 patients using the GEE model. Longitudinal analysis showed that the changes in anti-HMGCR IgG levels were significantly correlated with the changes in PGA VAS (β = 3.830; p < 0.0001), muscle VAS (β = 2.893; p < 0.0001), MMT8 (β=-19.368; p < 0.0001) and CK levels (β = 3900.05, p < 0.0001) (Supplementary Fig. 3). However, the changes in anti-HMGCR IgA and IgM levels were not associated with changes in disease activity (data not shown). Furthermore, changes in anti-HMGCR IgA levels were correlated with the changes in anti-HMGCR IgM levels (β = 0.885; p < 0.0001), but no correlation was found between levels of anti-HMGCR IgG levels and anti-HMGCR IgA or IgM levels (Supplementary Fig. 4).

We then analyzed the relationship between the changes in anti-HMGCR IgM levels and the changes in disease activity in six patients with three or more visits who had a history of anti-HMGCR IgM positivity. Four patients (P1, P2, P3, P4) were found to have progressive or persistent disease activity when anti-HMGCR IgM turned positive or remained positive, whereas no such pattern was found in some patients (P5, P6) (Fig. 3).

Fig. 3 Longitudinal relationship between anti-HMGCR IgM levels (red line) and PGA VAS (dark green line), muscle VAS (blue line) in six anti-HMGCR patients with three or more visits. Abbreviations: HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; PGA, Physician’s Global Assessment; VAS, Visual Analog Scale; GCs, glucocorticosteroid; DMARDS, disease-modifying anti-rheumatic drugs; tac, tacrolimus; IVIG, intravenous. immunoglobulin; MMF, mycophenolate mofetil; CTX, cyclophosphamide; CsA, ciclosporin A; HCQ, Hydroxychloroquine

Outcome of patients with anti-HMGCR-positive IMNM stratified by anti-HMGCR IgM

We evaluated the outcome of anti-HMGCR IgG patients stratified by anti-HMGCR IgM profiles. The follow-up time for all 71 patients ranged from 4 to 144 months, with a median time interval of 29.4 (18.8,45.3) months. One anti-HMGCR IgM-positive woman died of a cervical malignancy 20 months after being diagnosed with myositis. Eight anti-HMGCR IgM-negative patients (16.3%) achieved remission after 6 months, but no nti-HMGCR IgM-positive patients achieved remission after half a year. More anti-HMGCR IgM-positive patients at baseline developed chronic polycyclic and chronic continuous courses than anti-HMGCR IgM-negative patients (polycyclic course: 40% vs. 25%; chronic continuous course: 46.7% vs. 20.5%, p = 0.018) (Table 2).

We also evaluated the outcome of anti-HMGCR-positive patients stratified by anti-HMGCR IgM profiles during follow-up. There were 24 patients who developed positive for anti-HMGCR IgM antibodies during the course of the disease, and patients who were ever anti-HMGCR IgM positive also had a more refractory outcome (polycyclic course: 42.1% vs. 22.5%; chronic continuous course: 36.8% vs. 22.5%, p = 0.048) (Supplementary Table 4).

Table 2 Outcome of anti-HMGCR-positive patients stratified by anti-HMGCR IgM phenotype at baseline

Characteristics	All patients(N = 71)	Anti-HMGCR IgM + at baseline (n = 19)	Anti-HMGCR IgM- at baseline (n = 52)	p value	
Follow-up time(months)	29.4(18.8,45.3)	39.4(17.2,83.8)	28.6(18.9,42.1)	0.367	
Treatment					
 Corticosteroids steroids	61(85.9%)	17(89.5%)	44(84.6%)	0.719	
 Immunosuppressive agents	38(53.3%)	12(63.2%)	26(50%)	0.432	
 Intravenous. Immunoglobulin	16(22.5%)	5(26.3%)	11(21.2%)	0.750	
 Tocilizumab	7(9.9%)	2(10.5%)	5(9.6%)	1	
Outcome					
 Death	1(4.1%)	1(5.3%)	0	0.268	
 Remission at 6 months(n = 67)	8/67(11.9%)	0/8	8/49(16.3%)	0.097	
 Remission at 1 year(n = 66)	23/66(34.8%)	4/18(22.2%)	19/48(39.6%)	0.187	
 Remission at 2 years(n = 54)	23/54(42.6%)	5/15(33.3%)	18/39(46.2%)	0.393	
 Relapse (n = 49)	17/49(34.7%)	5/15(33.3%)	12/34(35.3%)	1	
Clinical course					
 Monocyclic	26/59(44.1%)	2/15(13.3%)	24/44(54.5%)		
 Polycyclic	17/59(28.8%)	6/15(40%)	11/44(25%)		
 Chronic continuous	16/59(27.1%)	7/15(46.7%)	9/44(20.5%)	0.018	

We used time to remission as the outcome indicator, and analyzed risk factors affecting the prognosis of anti-HMGCR-positive patients using univariate and multivariate analyses. Univariate analyses showed that the age of onset, statin history, ILD, and anti-HMGCR IgM positivity were associated with clinical remission (all p < 0.05). The pathological characteristics in Supplementary Table 2 were also included in the univariate analysis, and were not found to be associated with outcome (data not shown). Further multivariate Cox regression analysis revealed that older age of onset (HR 1.044, 95% CI 1.017–1.073, p = 0.001), and ILD (HR 2.989, 95% CI 1.319–6.777, p = 0.009) were favorable factors for the time to achieve remission (Table 3).

Table 3 Univariate and multivariate cox proportional hazard models of time-to-remission

Characteristics	Remission
(n = 35)	Non-remission
(n = 22)	Univariate analysis	Multivariate analysis	
HR (95%CI)	p value	HR (95%CI)	p value	
Female	25(71.4%)	14(63.6%)	1.523(0.722–3.211)	0.269			
Age of onset, median (IQR), years	49(32,66)	31(18,48)	1.051(1.028,1.074)	< 0.0001	1.044(1.017–1.073)	0.001	
Time from onset to diagnosis, months	12(6,19)	15(6,37)	0.992(0.977-1.007)	0.281			
Statin history	12(34.3%)	1(4.5%)	3.504(1.691–7.262)	0.001	1.744(0.750–4.059)	0.197	
Muscle weakness	32(91.4%)	21(95.5%)	0.416(0.125–1.387)	0.154			
 Severe muscle weakness (MRC ≤ 3)	20(57.1%)	19(86.4%)	0.586(0.298–1.154)	0.112			
 Dysphagia	8(22.9%)	4(18.2%)	0.954(0.430–2.115)	0.907			
 Neck weakness	13(37.1%)	10(45.5%)	1.258(0.627–2.521)	0.518			
 MMT8(> 60)	17(48.6%)	8(36.4%)	1.595(0.817–3.111)	0.171			
Muscle atrophy	1(2.9%)	4(18.2%)	0.328(0.044–2.419)	0.274			
Myalgia	9(25.7%)	4(18.2%)	1.204(0.562–2.582)	0.633			
Arthritis	3(8.6%)	3(13.6%)	1.617(0.491–5.331)	0.429			
Skin involvement	7(20%)	3(13.6%)	0.778(0.337–1.798)	0.557			
Interstitial lung diseases	9(25.7%)	0	3.047(1.405–6.607)	0.005	2.989(1.319–6.777)	0.009	
Malignant tumor	2(5.7%)	1(4.5%)	1.684(0.395–7.187)	0.481			
Other connective tissue diseases	3(8.6%)	2(9.1%)	0.782(0.236–2.594)	0.687			
CK, median (IQR), U/L	15(42.9%)	5(22.7%)	1.186(0.605–2.325)	0.618			
Anti-HMGCR IgG level (> 0.31U/mL)	19(54.3%)	12(54.5%)	0.667(0.339–1.312)	0.240			
Anti-HMGCR IgA positive(> 0.18U/ml)	8(22.9%)	8(36.4%)	1.085(0.477–2.470)	0.845			
Anti-HMGCR IgM positive (> 0.44U/L)	20(57.1%)	22(100%)	0.229(0.150–0.595)	0.001	1.145(0.513–2.557)	0.741	
Abbreviations: HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; IQR, interquartile range; MRC, Medical Research Council; MMT, manual muscle testing; CK, creatine kinase

Discussion

Anti-HMGCR antibodies are autoantibodies directed against the 100kd/200kd protein identified in 2010 and are considered to be one of the serum markers for IMNM [1, 3, 4]. Anti-HMGCR IgG is the only isotype of anti-HMGCR antibodies that has been reported and studied to date. Previous studies have shown that anti-HMGCR-positive patients with statin exposure and younger age tend to have a worse prognosis [5–8]. Anti-HMGCR Ig G levels correlate with disease activity in cross-sectional and longitudinal analyses [3, 9–11]. However, the distribution, clinical association, and prognostic associations of anti-HMGCR isotypes in IMNM have not been investigated.

This study found that anti-HMGCR Ig M levels correlated with disease activity at baseline, and anti-HMGCR IgG levels were associated with disease activity in both cross-sectional and longitudinal analyses. We also found that Ig M and IgA antibodies were more likely to have a switch between positive and negative than IgG antibodies during the course of the disease, and that Ig A and Ig M levels were correlated with each other at both baseline and follow-up. Our study also found that more anti-HMGCR IgM-positive patients tended to have a refractory course.

Our study shows that anti-HMGCR IgG levels are associated with CK levels and muscle strength both at baseline and during follow-up, which is consistent with previous study findings [3, 9–11]. Previous studies on the pathology and pathogenesis of IMNM have shown that exposure of overexpressed HMGCR proteins on the endoplasmic reticulum induces the production of anti-HMGCR antibodies, and activates the Th1-M1-mediated immune response system, leading to necrosis, atrophy, and macrophagocytosis of muscle fibers [12–14, 23].Immunosuppressive treatment suppresses over-activation of the immune system, followed by a decrease in anti-HMGCR IgG titers and recovery of muscle strength, which may explain the association between anti-HMGCR IgG levels and disease activity.

This study showed that persistent anti-HMGCR IgM positivity often indicates a prolonged disease course and poor response to treatment, and the occurrence of IgM positive conversion is often associated with relapse (Fig. 3; Table 2). The relationship between autoantibody isotypes and disease course and prognosis has been extensively studied in other diseases. For example, the IgM type of anti-topoisomerase I antibody is associated with disease progression in systemic sclerosis [24], and the IgM type of rheumatoid factor is associated with disease severity in rheumatoid arthritis [25, 26]. IgM is the first antibody produced after antigen exposure during the primary humoral immune response, and the presence of IgM-type antibodies often indicates recent immune activation and damage. Therefore, IgM levels of anti-HMGCR may reflect disease activity to some extent. Meanwhile, the amplified complement-killing effect of the pentameric structure of Ig M-type antibodies may also contribute to the association of anti-HMGCR Ig M with poor prognosis [27]. In addition, the antigenic epitopes recognized by anti-HMGCR IgM and IgA antibodies on muscle biopsies and their pathogenic mechanisms deserve further investigation.

In this study, we found that anti-HMGCR Ig M and IgA antibodies were more prone to antibody acquisition or disappearance during follow-up, which may be related to the fact that Ig M-type antibodies are produced first after antigen exposure, and plasma cells producing Ig M-type antibodies have a shorter lifespan [28]. We also found that the levels of anti-HMGCR IgA and IgM were correlated with each other both at baseline and during follow-up, which may be related to the class switching between Ig M, Ig G, and IgA antibodies [29].

In the analyses of prognostic risk factors, we found that younger age of onset and no ILD were risk factors for achieving remission. Previous studies have also found that younger patients have a worse prognosis in IMNM [5–8, 30].

The present study had several limitations. First, because we only included patients who were positive for anti-HMGCR IgG at baseline, we cannot exclude the possibility that some IMNM patients were only positive for anti-HMGCR IgM and/or IgA. However, the specificity of anti-HMGCR IgM/IgA was greater than 85%, regardless of the use of mean + 2SD/mean + 3SD as cut-off values. The effect of muscle pathology on antibody isotypes and prognosis may require further investigation. In addition, follow-up data on antibody isotypes were available for less than half of the patients, and the findings of this study need to be validated with more follow-up data in a larger cohort.

In conclusion, this study investigated the changes of anti-HMGCR antibody isotypes during the course of the disease, and found that the presence of anti-HMGCR IgM was associated with a refractory disease course. Further research for anti-HMGCR IgM epitopes and immune response mechanisms will help to better understand the pathogenesis of anti-HMGCR-positive IMNM and find more effective treatments.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Acknowledgements

We would like to thank the National High Level Hospital Clinical Research Funding and Natural Science Foundation of Beijing Municipality for their support of our research. We also thank all members of the Department of Rheumatology at China-Japan Friendship Hospital for their help and assistance. We also thank to our patients for their trust in our department and their cooperation in research.

Author contributions

All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. Dr. Xin Lu had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. X. Lu were responsible for conception and design of the study. HX. Yang drafted the article or revised it critically for important intellectual content. GC. Wang, and QL. Peng contributed to acquisition and analysis of data. HX. Yang, C. Sun, LF. Ye, YT. Xu, S. Lin contributed to data analysis and interpretation.

Funding

This study was supported by the National High Level Hospital Clinical Research Funding (2022-NHLHCRF-YS-02), and Natural Science Foundation of Beijing Municipality (No. 7232145).

Data availability

Data is provided within the manuscript or supplementary information files.

Declarations

Ethics approval and consent to participate

This study was approved by the Ethics Committee of the China-Japan Friendship Hospital (2019-SDZL-3).

Consent for publication

All participants signed an informed consent agreement.

Competing interests

The authors declare no competing interests.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
Refrences

1. Nishino I, Hilton-Jones D, Stenzel W, Allenbach Y, de Groot I, Amato A et al. 224th ENMC International Workshop: Neuromuscul Disord. 2017;28:87–99.
2. Allenbach Y Benveniste O Stenzel W Boyer O Immune-mediated necrotizing myopathy: clinical features and pathogenesis Nat Rev Rheumatol 2020 16 689 701 10.1038/s41584-020-00515-9 33093664
Allenbach Y, Benveniste O, Stenzel W, Boyer O. Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nat Rev Rheumatol. 2020;16:689–701.33093664 10.1038/s41584-020-00515-9
3. Allenbach Y Drouot L Rigolet A Charuel JL Jouen F Romero NB Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: Inconstant exposure to statin Med (United States) 2014 93 150 7
Allenbach Y, Drouot L, Rigolet A, Charuel JL, Jouen F, Romero NB, et al. Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: Inconstant exposure to statin. Med (United States). 2014;93:150–7.
4. Christopher-Stine L Casciola-Rosen LA Hong G Chung T Corse AM Mammen AL A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy Arthritis Rheum 2010 62 2757 66 10.1002/art.27572 20496415
Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum. 2010;62:2757–66.20496415 10.1002/art.27572
5. Tiniakou E Pinal-Fernandez I Lloyd TE Albayda J Paik J Werner JL More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutarylcoenzyme A reductase-associated autoimmune myopathy Rheumatol (United Kingdom) 2017 56 787 94
Tiniakou E, Pinal-Fernandez I, Lloyd TE, Albayda J, Paik J, Werner JL, et al. More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutarylcoenzyme A reductase-associated autoimmune myopathy. Rheumatol (United Kingdom). 2017;56:787–94.
6. Liang WC Uruha A Suzuki S Murakami N Takeshita E Chen WZ Pediatric necrotizing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies Rheumatol (United Kingdom) 2017 56 287 93
Liang WC, Uruha A, Suzuki S, Murakami N, Takeshita E, Chen WZ, et al. Pediatric necrotizing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies. Rheumatol (United Kingdom). 2017;56:287–93.
7. Tansley SL Betteridge ZE Simou S Jacques TS Pilkington C Wood M Anti-HMGCR autoantibodies in juvenile idiopathic inflammatory myopathies identify a rare but clinically important subset of patients J Rheumatol 2017 44 488 92 10.3899/jrheum.160871 28202739
Tansley SL, Betteridge ZE, Simou S, Jacques TS, Pilkington C, Wood M, et al. Anti-HMGCR autoantibodies in juvenile idiopathic inflammatory myopathies identify a rare but clinically important subset of patients. J Rheumatol. 2017;44:488–92.28202739 10.3899/jrheum.160871
8. Mohassel P, Landon-Cardinal O, Foley AR, Donkervoort S, Pak KS, Wahl C et al. Anti-HMGCR myopathy may resemble limb-girdle muscular dystrophy. Neurol Neuroimmunol NeuroInflammation. 2019;6.
9. Ge Y Lu X Peng Q Shu X Wang G Clinical characteristics of anti-3-hydroxy-3-methylglutaryl coenzyme a reductase antibodies in Chinese patients with idiopathic inflammatory myopathies PLoS ONE 2015 10 1 9 10.1371/journal.pone.0141616
Ge Y, Lu X, Peng Q, Shu X, Wang G. Clinical characteristics of anti-3-hydroxy-3-methylglutaryl coenzyme a reductase antibodies in Chinese patients with idiopathic inflammatory myopathies. PLoS ONE. 2015;10:1–9.10.1371/journal.pone.0141616
10. Werner JL Christopher-Stine L Ghazarian SR Pak KS Kus JE Daya NR Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy Arthritis Rheum 2012 64 4087 93 10.1002/art.34673 22933019
Werner JL, Christopher-Stine L, Ghazarian SR, Pak KS, Kus JE, Daya NR, et al. Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum. 2012;64:4087–93.22933019 10.1002/art.34673
11. Ramanathan S Langguth D Hardy TA Garg N Bundell C Rojana-Udomsart A Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy Neurol Neuroimmunol NeuroInflammation 2015 2 e96 10.1212/NXI.0000000000000096
Ramanathan S, Langguth D, Hardy TA, Garg N, Bundell C, Rojana-Udomsart A, et al. Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy. Neurol Neuroimmunol NeuroInflammation. 2015;2:e96.10.1212/NXI.0000000000000096
12. Allenbach Y Arouche-Delaperche L Preusse C Radbruch H Butler-Browne G Champtiaux N Necrosis in anti-SRP + and anti-HMGCR + myopathies Neurology 2018 90 e507 17 10.1212/WNL.0000000000004923 29330311
Allenbach Y, Arouche-Delaperche L, Preusse C, Radbruch H, Butler-Browne G, Champtiaux N, et al. Necrosis in anti-SRP + and anti-HMGCR + myopathies. Neurology. 2018;90:e507–17.29330311 10.1212/WNL.0000000000004923
13. Bergua C Chiavelli H Allenbach Y Arouche-Delaperche L Arnoult C Bourdenet G In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy Ann Rheum Dis 2019 78 131 9 10.1136/annrheumdis-2018-213518 30309969
Bergua C, Chiavelli H, Allenbach Y, Arouche-Delaperche L, Arnoult C, Bourdenet G, et al. In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy. Ann Rheum Dis. 2019;78:131–9.30309969 10.1136/annrheumdis-2018-213518
14. Arouche-Delaperche L Allenbach Y Amelin D Preusse C Mouly V Mauhin W Pathogenic role of anti–signal recognition protein and anti–3-Hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies Ann Neurol 2017 81 538 48 10.1002/ana.24902 28224701
Arouche-Delaperche L, Allenbach Y, Amelin D, Preusse C, Mouly V, Mauhin W, et al. Pathogenic role of anti–signal recognition protein and anti–3-Hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies. Ann Neurol. 2017;81:538–48.28224701 10.1002/ana.24902
15. Lundberg IE Tjärnlund A Bottai M Werth VP Pilkington C de Visser M 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups Ann Rheum Dis 2017 76 1955 64 10.1136/annrheumdis-2017-211468 29079590
Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76:1955–64.29079590 10.1136/annrheumdis-2017-211468
16. Travis WD Costabel U Hansell DM King TE Lynch DA Nicholson AG An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias Am J Respir Crit Care Med 2013 188 733 48 10.1164/rccm.201308-1483ST 24032382
Travis WD, Costabel U, Hansell DM, King TE, Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733–48.24032382 10.1164/rccm.201308-1483ST
17. Suzuki S Hayashi YK Kuwana M Tsuburaya R Suzuki N Nishino I Myopathy associated with antibodies to signal recognition particle: disease progression and neurological outcome Arch Neurol 2012 69 728 32 10.1001/archneurol.2011.1728 22332183
Suzuki S, Hayashi YK, Kuwana M, Tsuburaya R, Suzuki N, Nishino I. Myopathy associated with antibodies to signal recognition particle: disease progression and neurological outcome. Arch Neurol. 2012;69:728–32.22332183 10.1001/archneurol.2011.1728
18. Sultan SM Allen E Oddis CV Kiely P Cooper RG Lundberg IE Reliability and validity of the myositis disease activity assessment tool Arthritis Rheum 2008 58 3593 9 10.1002/art.23963 18975333
Sultan SM, Allen E, Oddis CV, Kiely P, Cooper RG, Lundberg IE, et al. Reliability and validity of the myositis disease activity assessment tool. Arthritis Rheum. 2008;58:3593–9.18975333 10.1002/art.23963
19. Rider LG Werth VP Huber AM Alexanderson H Rao AP Ruperto N Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis Arthritis Care Res 2011 63 118 57 10.1002/acr.20532
Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis. Arthritis Care Res. 2011;63:118–57.10.1002/acr.20532
20. Miller FW. New approaches to the assessment and treatment of the idiopathic inflammatory myopathies. Ann Rheum Dis. 2012;71.
21. Rider LG Aggarwal R Machado PM Hogrel JY Reed AM Christopher-Stine L Ruperto N Update on outcome assessment in myositis Nat Rev Rheumatol 2018 14 5 303 18 10.1038/nrrheum.2018.33 29651119
Rider LG, Aggarwal R, Machado PM, Hogrel JY, Reed AM, Christopher-Stine L, Ruperto N. Update on outcome assessment in myositis. Nat Rev Rheumatol. 2018;14(5):303–18.29651119 10.1038/nrrheum.2018.33
22. Selva-O’Callaghan A Labrador-Horrillo M Solans-Laque R Simeon-Aznar CP Martínez-Gómez X Vilardell-Tarrés M Myositis-specific and myositis-associated antibodies in a series of eighty-eight mediterranean patients with idiopathic inflammatory myopathy Arthritis Care Res 2006 55 791 8 10.1002/art.22237
Selva-O’Callaghan A, Labrador-Horrillo M, Solans-Laque R, Simeon-Aznar CP, Martínez-Gómez X, Vilardell-Tarrés M. Myositis-specific and myositis-associated antibodies in a series of eighty-eight mediterranean patients with idiopathic inflammatory myopathy. Arthritis Care Res. 2006;55:791–8.10.1002/art.22237
23. Pinal-fernandez I Amici DR Parks CA Derfoul A Casal-dominguez M Pak K Myositis Autoantigen Expression Correlates Muscle Regeneration but Not Autoantibody Specif 2019 71 1371 6 30861336
Pinal-fernandez I, Amici DR, Parks CA, Derfoul A, Casal-dominguez M, Pak K, et al. Myositis Autoantigen Expression Correlates Muscle Regeneration but Not Autoantibody Specif. 2019;71:1371–6.30861336
24. Boonstra M Bakker JA Grummels A Ninaber MK Ajmone Marsan N Wortel CM Association of anti–topoisomerase I antibodies of the IgM Isotype with Disease Progression in anti–topoisomerase I–Positive systemic sclerosis Arthritis Rheumatol 2020 72 1897 904 10.1002/art.41403 32840062
Boonstra M, Bakker JA, Grummels A, Ninaber MK, Ajmone Marsan N, Wortel CM, et al. Association of anti–topoisomerase I antibodies of the IgM Isotype with Disease Progression in anti–topoisomerase I–Positive systemic sclerosis. Arthritis Rheumatol. 2020;72:1897–904.32840062 10.1002/art.41403
25. Rantapää-Dahlqvist S De Jong BAW Berglin E Hallmans G Wadell G Stenlund H Antibodies against Cyclic Citrullinated Peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis Arthritis Rheum 2003 48 2741 9 10.1002/art.11223 14558078
Rantapää-Dahlqvist S, De Jong BAW, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against Cyclic Citrullinated Peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003;48:2741–9.14558078 10.1002/art.11223
26. Berglin E Johansson T Sundin U Jidell E Wadell G Hallmans G Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset Ann Rheum Dis 2006 65 453 8 10.1136/ard.2005.041376 16176994
Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G, et al. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis. 2006;65:453–8.16176994 10.1136/ard.2005.041376
27. Boes M Role of natural and immune IgM antibodies in immune responses Mol Immunol 2000 37 1141 9 10.1016/S0161-5890(01)00025-6 11451419
Boes M. Role of natural and immune IgM antibodies in immune responses. Mol Immunol. 2000;37:1141–9.11451419 10.1016/S0161-5890(01)00025-6
28. Bashford-Rogers RJM Bergamaschi L McKinney EF Pombal DC Mescia F Lee JC Analysis of the B cell receptor repertoire in six immune-mediated diseases Nature 2019 574 122 6 10.1038/s41586-019-1595-3 31554970
Bashford-Rogers RJM, Bergamaschi L, McKinney EF, Pombal DC, Mescia F, Lee JC, et al. Analysis of the B cell receptor repertoire in six immune-mediated diseases. Nature. 2019;574:122–6.31554970 10.1038/s41586-019-1595-3
29. Manis JP Tian M Alt FW Mechanism and control of class-switch recombination Trends Immunol 2002 23 31 9 10.1016/S1471-4906(01)02111-1 11801452
Manis JP, Tian M, Alt FW. Mechanism and control of class-switch recombination. Trends Immunol. 2002;23:31–9.11801452 10.1016/S1471-4906(01)02111-1
30. Lim J, Rietveld A, De Bleecker JL, Badrising UA, Saris CGJ, Van Der Kooi AJ et al. Seronegative patients form a distinctive subgroup of immune-mediated necrotizing myopathy. Neurol Neuroimmunol NeuroInflammation. 2019;6.
